Literature DB >> 21172357

Caveolin-1 negatively regulates a metalloprotease-dependent epidermal growth factor receptor transactivation by angiotensin II.

Akira Takaguri1, Heigoro Shirai, Keita Kimura, Akinari Hinoki, Kunie Eguchi, MaryEllen Carlile-Klusacek, Baohua Yang, Victor Rizzo, Satoru Eguchi.   

Abstract

A metalloprotease, ADAM17, mediates the generation of mature ligands for the epidermal growth factor receptor (EGFR). This is the key signaling step by which angiotensin II (AngII) induces EGFR transactivation leading to hypertrophy and migration of vascular smooth muscle cells (VSMCs). However, the regulatory mechanism of ADAM17 activity remains largely unclear. Here we hypothesized that caveolin-1 (Cav1), the major structural protein of a caveolae, a membrane microdomain, is involved in the regulation of ADAM17. In cultured VSMCs, infection of adenovirus encoding Cav1 markedly inhibited AngII-induced EGFR ligand shedding, EGFR transactivation, ERK activation, hypertrophy and migration, but not intracellular Ca(2+) elevation. Methyl-β-cyclodextrin and filipin, reagents that disrupt raft structure, both stimulated an EGFR ligand shedding and EGFR transactivation in VSMCs. In addition, non-detergent sucrose gradient membrane fractionations revealed that ADAM17 cofractionated with Cav1 in lipid rafts. These results suggest that lipid rafts and perhaps caveolae provide a negative regulatory environment for EGFR transactivation linked to vascular remodeling induced by AngII. These novel findings may provide important information to target cardiovascular diseases under the enhanced renin angiotensin system.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21172357      PMCID: PMC3035769          DOI: 10.1016/j.yjmcc.2010.12.009

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  40 in total

Review 1.  Caveolin-dependent angiotensin II type 1 receptor signaling in vascular smooth muscle.

Authors:  Masuko Ushio-Fukai; R Wayne Alexander
Journal:  Hypertension       Date:  2006-10-02       Impact factor: 10.190

Review 2.  Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system.

Authors:  Puja K Mehta; Kathy K Griendling
Journal:  Am J Physiol Cell Physiol       Date:  2006-07-26       Impact factor: 4.249

Review 3.  AT(1) receptors and control of blood pressure: the kidney and more...

Authors:  Steven D Crowley; Susan B Gurley; Thomas M Coffman
Journal:  Trends Cardiovasc Med       Date:  2007-01       Impact factor: 6.677

4.  ErbB-4 and TNF-alpha converting enzyme localization to membrane microdomains.

Authors:  Kristina W Thiel; Graham Carpenter
Journal:  Biochem Biophys Res Commun       Date:  2006-09-28       Impact factor: 3.575

Review 5.  Vascular signaling through cholesterol-rich domains: implications in hypertension.

Authors:  Glaucia E Callera; Augusto Ci Montezano; Alvaro Yogi; Rita Ca Tostes; Rhian M Touyz
Journal:  Curr Opin Nephrol Hypertens       Date:  2007-03       Impact factor: 2.894

6.  Central role of Gq in the hypertrophic signal transduction of angiotensin II in vascular smooth muscle cells.

Authors:  Haruhiko Ohtsu; Sadaharu Higuchi; Heigoro Shirai; Kunie Eguchi; Hiroyuki Suzuki; Akinari Hinoki; Eugen Brailoiu; Andrea D Eckhart; Gerald D Frank; Satoru Eguchi
Journal:  Endocrinology       Date:  2008-03-20       Impact factor: 4.736

7.  Endothelial cytoskeletal reorganization in response to PAR1 stimulation is mediated by membrane rafts but not caveolae.

Authors:  Maryellen Carlile-Klusacek; Victor Rizzo
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-03-16       Impact factor: 4.733

8.  Novel role of protein kinase C-delta Tyr 311 phosphorylation in vascular smooth muscle cell hypertrophy by angiotensin II.

Authors:  Hidekatsu Nakashima; Gerald D Frank; Heigoro Shirai; Akinari Hinoki; Sadaharu Higuchi; Haruhiko Ohtsu; Kunie Eguchi; Archana Sanjay; Mary E Reyland; Peter J Dempsey; Tadashi Inagami; Satoru Eguchi
Journal:  Hypertension       Date:  2008-01-07       Impact factor: 10.190

9.  Caveolin-1 sensitizes vascular smooth muscle cells to mildly oxidized LDL-induced apoptosis.

Authors:  Cécile Ingueneau; Uyen Huynh-Do; Jean-Claude Thiers; Anne Nègre-Salvayre; Robert Salvayre; Cécile Vindis
Journal:  Biochem Biophys Res Commun       Date:  2008-03-06       Impact factor: 3.575

Review 10.  Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology.

Authors:  Sadaharu Higuchi; Haruhiko Ohtsu; Hiroyuki Suzuki; Heigoro Shirai; Gerald D Frank; Satoru Eguchi
Journal:  Clin Sci (Lond)       Date:  2007-04       Impact factor: 6.124

View more
  24 in total

1.  Overexpression of sigma-1 receptor inhibits ADAM10 and ADAM17 mediated shedding in vitro.

Authors:  Juan Li; Bin Liu; Xiaofei Gao; Zhixing Ma; Tianyi CaoSong; Yan-ai Mei; Yufang Zheng
Journal:  Protein Cell       Date:  2012-02-09       Impact factor: 14.870

2.  Role of Adipose Tissue Endothelial ADAM17 in Age-Related Coronary Microvascular Dysfunction.

Authors:  Huijuan Dou; Attila Feher; Alec C Davila; Maritza J Romero; Vijay S Patel; Vinayak M Kamath; Monika Beck Gooz; R Daniel Rudic; Rudolf Lucas; David J Fulton; Neal L Weintraub; Zsolt Bagi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-05-04       Impact factor: 8.311

3.  Vascular ADAM17 as a Novel Therapeutic Target in Mediating Cardiovascular Hypertrophy and Perivascular Fibrosis Induced by Angiotensin II.

Authors:  Takehiko Takayanagi; Steven J Forrester; Tatsuo Kawai; Takashi Obama; Toshiyuki Tsuji; Katherine J Elliott; Elisa Nuti; Armando Rossello; Hang Fai Kwok; Rosario Scalia; Victor Rizzo; Satoru Eguchi
Journal:  Hypertension       Date:  2016-08-01       Impact factor: 10.190

Review 4.  Novel tyrosine kinase signaling pathways: implications in vascular remodeling.

Authors:  Sri N Batchu; Vyacheslav A Korshunov
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-03       Impact factor: 2.894

5.  Caveolin-1 Deletion Prevents Hypertensive Vascular Remodeling Induced by Angiotensin II.

Authors:  Steven J Forrester; Katherine J Elliott; Tatsuo Kawai; Takashi Obama; Michael J Boyer; Kyle J Preston; Zhen Yan; Satoru Eguchi; Victor Rizzo
Journal:  Hypertension       Date:  2016-11-28       Impact factor: 10.190

Review 6.  Angiotensin II Signal Transduction: An Update on Mechanisms of Physiology and Pathophysiology.

Authors:  Steven J Forrester; George W Booz; Curt D Sigmund; Thomas M Coffman; Tatsuo Kawai; Victor Rizzo; Rosario Scalia; Satoru Eguchi
Journal:  Physiol Rev       Date:  2018-07-01       Impact factor: 37.312

7.  Caveolin 1 is critical for abdominal aortic aneurysm formation induced by angiotensin II and inhibition of lysyl oxidase.

Authors:  Takehiko Takayanagi; Kevin J Crawford; Tomonori Kobayashi; Takashi Obama; Toshiyuki Tsuji; Katherine J Elliott; Tomoki Hashimoto; Victor Rizzo; Satoru Eguchi
Journal:  Clin Sci (Lond)       Date:  2014-06       Impact factor: 6.124

8.  A repressor protein, Mnt, is a novel negative regulator of vascular smooth muscle cell hypertrophy by angiotensin II and neointimal hyperplasia by arterial injury.

Authors:  Takehiko Takayanagi; Akito Eguchi; Akira Takaguri; Akinari Hinoki; Allison M Bourne; Katherine J Elliott; Peter J Hurlin; Satoru Eguchi
Journal:  Atherosclerosis       Date:  2013-03-13       Impact factor: 5.162

9.  ADAM17 silencing by adenovirus encoding miRNA-embedded siRNA revealed essential signal transduction by angiotensin II in vascular smooth muscle cells.

Authors:  Katherine J Elliott; Allison M Bourne; Takehiko Takayanagi; Akira Takaguri; Tomonori Kobayashi; Kunie Eguchi; Satoru Eguchi
Journal:  J Mol Cell Cardiol       Date:  2013-05-17       Impact factor: 5.000

10.  Vascular induction of a disintegrin and metalloprotease 17 by angiotensin II through hypoxia inducible factor 1α.

Authors:  Takashi Obama; Takehiko Takayanagi; Tomonori Kobayashi; Allison M Bourne; Katherine J Elliott; Martine Charbonneau; Claire M Dubois; Satoru Eguchi
Journal:  Am J Hypertens       Date:  2014-05-28       Impact factor: 2.689

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.